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ABSTRACT
OBJECTIVE: To assess the prevalence and factors associated with cost-related underuse of 
medications in a nationally representative sample of Brazilians aged 50 years and over.
METHODS: Among the 9,412 participants of the Brazilian Longitudinal Study of Aging (ELSI-
Brazil), 6,014 reported using at least one medication on regular basis and were included in the 
analysis. Underuse of medications was by stopping taking or reducing the number of tablets 
or the dose of any prescribed medication for financial reasons. The theoretical framework used 
for the selection of the exploratory variables included predisposing factors, enabling factors, 
and factors of need. Associations were tested by Poisson regression.
RESULTS: The prevalence of underuse of medications was 10.6%. After adjustments for relevant 
covariables, positive and statistically significant associations (p < 0.05) with the outcome were 
found for females [prevalence ratio (PR) = 1.39], sufficiency of the family income for expenses 
(PR = 1.74 for sometimes and PR 2.42 for never), frequency with which the physician explains 
about the disease and treatment (PR = 1.31 for rarely or never), number of medications used 
(PR = 1.39 for 2–4 and 1.53 for 5 or more), fair (PR = 2.02) and poor or very poor self-rated health 
(PR = 2.92), and a previous medical diagnosis of depression (PR = 1.69). Negative associations 
were observed for the age groups of 60–79 years (PR = 0.75) and 80 years and over (PR = 0.43), 
socioeconomic status of the household (PR = 0.70, 0.79, and 0.60 for the second, third, and fourth 
quartile, respectively), and private health plan coverage (PR = 0.79). There were no associations 
between hypertension and self-reported diabetes and underuse of medications.
CONCLUSIONS: Cost-related underuse of medications is multidimensional and complex, and 
it covers socio-demographic characteristics, health conditions, and the use of health services. 
The explanation about the disease and its treatment to the patient and the expansion of the 
universal access to pharmaceutical care can minimize the risks of underuse.
DESCRIPTORS: Underuse of Medications. Prescription Drugs. Health of the Older Adults. 
Cross-Sectional Study. Pharmacoepidemiology.
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INTRODUCTION
Medication use increases with age in terms of frequency (prevalence of use in the population) 
and intensity (amount of medications used)1. This is due to the greater presence of diseases 
and chronic conditions, whose treatment has an important support in pharmacotherapy2. 
This greater use results in a complex therapeutic regimen, intensifies adverse drug reactions 
(especially in aged organisms), and increases costs3, which may lead to non-adherence to 
prescribed treatment.
Underuse of medications is a type of non-adherence to drug treatment. There are different 
types of underuse, such as not acquiring all prescribed medications, reducing the number 
of tablets, or changing the dose used4. Underuse may be the last obstacle to the access to an 
effective therapy, when other barriers (inaccessibility to service and inadequate prescriptions) 
are overcome. It compromises the effectiveness of treatment, which increases health risks and, 
consequently, overload health services5. The increase in the price of medications, the different 
mechanisms that cover their costs (public or private), and the user’s purchasing power are the 
main reasons for cost-related underuse of medications, but they are not their only determinants4.
International studies have reported  that, in addition to contextual financial pressures and 
the organization of health services, other factors influence the underuse of medications, 
such as sociodemographic characteristics (sex, age, education level) and health conditions 
(self-rated health and chronic diseases)6–11.
In Brazil, two studies have investigated cost-related underuse of medications among older persons 
living in the Metropolitan Region of Belo Horizonte12,13, but no previous study has investigated 
this issue in a nationally based sample of older Brazilians. Thus, this study aimed to investigate 
the prevalence and individual factors associated with cost-related underuse of medications in 
a nationally representative sample  of the Brazilian population aged 50 years and over.
METHODS
Study population
This cross-sectional study used baseline data from the Brazilian Longitudinal Study of 
Aging (ELSI-Brazil), which is a nationwide population-based study on the living, health, 
and well-being conditions of the Brazilian population aged 50 years and over. The baseline 
survey was conducted in 2015 and 2016. The sampling design was based on selection stages, 
which combined municipality, census tract, and household. Municipalities were allocated 
in four strata according to their population size: (1) ≤ 26,700 inhabitants, (2) 26,701–135,000 
inhabitants, (3) 135,001–750,000 inhabitants, and (4) > 750000 inhabitants. In the first three 
strata, sampling was carried out in three stages (municipalities, census tract, and household); 
in the fourth stratum, all municipalities were selected and the sampling was carried out in 
two stages (census tract and household). All persons aged 50 years and over living in the 
sampled households were considered eligible for the study. Sample size was defined as 10,000 
persons (9,412 participated). For our investigation, we selected the participants who reported 
using one or more medications prescribed by a physician on a regular basis (n = 6,647). This 
and other data for this analysis were obtained with face-to-face interviews conducted at the 
household. More details on the ELSI-Brazil can be seen in another publication14.
Variables and Data Collection
The outcome variable was cost-related underuse of medications, measured by the question: 
“In the last 30 days, because of financial problems, did you: (a) stopped taking, (b) decreased 
the number of, (c) decreased the dose of (dividing the tablet or taking fewer doses) any 
medication prescribed by a physician?”. We considered underuse the positive answer to 
any of the alternatives.
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Exposure variables were selected based on the behavioral model of access and use of 
health services of Andersen15. This model lists the predisposing factors (sociodemographic 
characteristics), enabling factors (community and individual resources that favor or hinder 
access to services), and factors of need (health conditions) to explain the event. Although 
this theoretical framework was initially proposed to analyze the use of health services, the 
model has supported studies on the use of medications2,7,10,13. In this analysis, the predisposing 
factors included sex, age (50–59, 60–79, ³ 80 years), years of schooling (0, 1–10, 11 or more), 
marital status (married, single or separated, widow/widowed), and living arrangements 
(living alone or not). The enabling factors were region of residence, socioeconomic status of 
the household, sufficiency of the family income for expenses, health plan coverage, frequency 
with which the physician explains about the disease and the proposed treatment, and number 
of medications used. The socioeconomic position of the household was measured by a score 
created through principal component analysis16, which considered the number of household 
appliances and number of vehicles, in addition to the presence of domestic workers. Factors 
of need were self-rated health and history of medical diagnosis of hypertension and diabetes.
Data Analysis
Initially, we examined the distribution of characteristics of the study participants according 
to the underuse of medications using Pearson’s chi-square test with Rao-Scott correction. The 
analyses of the associations were based on prevalence ratios and 95% confidence intervals, which 
were estimated by univariate and multivariate Poisson regression, with robust variance. The 
multivariate models included those variables that showed associations with the outcome at 
p < 0.20 level (Wald test) in the univariate analysis. The multivariate analysis started with the full 
model, followed by the selective deletion of variables according to the p value (backward), and 
successive models were compared by the likelihood-ratio test. The adequacy of the final model 
was evaluated by  deviance statistics (p > 0.05). Those variables that showed an association 
with the outcome at p < 0.05 level were considered as independently associated with underuse 
of medication. Statistical analysis was conducted using the software Stata®, version 14.0, 
considering the sample weight of the individuals and the sample parameters (svy command).
The ELSI-Brazil was approved by the Research Ethics Committee of the Instituto de Pesquisas 
René Rachou of the Fundação Oswaldo Cruz, Minas Gerais (CAAE 34649814.3.0000.5091). 
All participants signed the informed consent.
RESULTS
Of the 6,647 persons eligible for the study, 6,014 participated in this analysis. Exclusions 
were due to incomplete information of at least one of the variables considered. Excluded 
individuals did not differ from the participants in relation to sex and age (p > 0.05). Among 
participants, mean age was 64.3 years (SD = 10.0) and females were predominant (59.2%).
The prevalence of underuse of medications in the last 30 days was 10.6% (95%CI 9.3-12.1) 
and it was higher among women (12.5%; 95%CI 10.7–14.6) than among men (7.9%; 95%CI 
6.8–8.2). This prevalence decreased progressively with age, in both sexes (Figure).
Table 1 shows the results of the univariate analyses of the associations between predisposing 
factors and underuse of medications. There were statistically significant associations 
(p < 0.05) with the female sex, widowhood, and education level. No association was found 
with living alone (p = 0.084).
All the enabling factors, except for geographical region (p = 0.278), showed statistically 
significant associations with underuse of medications (Table 2). They are: socioeconomic 
status of the household, sufficiency of income for expenses, private health plan coverage, 
explanation of the disease and treatment by the physician, and number of medical visits 
and medications used.
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Self-rated health and history of medical diagnosis of depression showed statistically 
significant associations with underuse of medications. The history of medical diagnosis 
of hypertension and diabetes  was not found to be  associated with the outcome [p = 0.293 
















Figure. Prevalence of cost-related underuse of medications according to age group, for total population, 
and stratified by sex. Brazilian Longitudinal Study of Aging (ELSI-Brazil), 2015–2016.
Table 1. Distribution of predisposing variables according to cost-related underuse of medications. 








Male 2,278 7.9 1.00
Female 3,736 12.5 1.58 1.31–1.91
Age (years)
50–59 2,133 14.0 1.00 < 0.001
60–79 3,284 8.9 0.64 0.53–0.77
80 and over 597 4.6 0.33 0.22–0.51
Education level (years) 0.012
Zero 949 12.3 1.00
1–10 3,756 11.4 0.93 0.74–1.16
11 or more 1,309 7.8 0.63 0.47–0.85
Marital status 0.014
Married 3,443 10.6 1.00
Single/Separated 1,278 12.9 1.21 0.99–1.41
Widow/Widowed 1,293 8.2 0.78 0.61–0.99
Living alone 0.084
No 5,241 10.8 1.00
Yes 773 8.8 0.81 0.63–1.06
a Unweighted. 
b Weighted by sampling design
c PR (95%CI): prevalence ratio (95% confidence interval), estimated by Poisson regression model with robust variance.
d Pearson’s chi-square test, for comparison of proportions, with Rao-Scott correction. 
5s
Underuse of medications Loyola Filho AI et al.
https://doi.org/10.11606/S1518-8787.2018052000622
The final results of the multivariate analysis of the factors associated with underuse of 
medications are presented in Table 4. Among those predisposing factors, independent 
and statistically significant associations (p < 0.05) were found for female sex (PR = 1.39) 
and age (PR = 0.75 and 0.43 for the age group of 60–79 and 80 years and over, respectively, 
compared to younger persons). Regarding enabling factors, the socioeconomic status of the 
household (RP = 0.70, 0.79, and 0.60 for the second, third, and fourth quartiles (in relation 
to the first one), respectively) and private health insurance coverage (PR = 0.79) showed 
negative associations. Positive associations  were found for sufficiency of family income for 
expenses (RP = 1.74 and 2.94 for sometimes and never, respectively, compared to always), 
frequency with which the physician explains about the disease and treatment (PR = 1, 31 
for rarely or never), and number of medications used (PR = 1.39 for 2–4 and 1.53 for 5 or 
more). Among factors of need, poorer self-rated health (PR = 2.02 and 2.92 for fair and poor 
or very poor, respectively) and history of medical diagnosis of depression (PR = 1.69) showed 
positive associations.
Table 2. Distribution of enabling variables according to cost-related underuse of medications. Brazilian 









Southeast 2,697 10.2 1.00
Northeast 1,501 12.2 1.20 0.97–1.47
North 353 14.2 1.39 0.99–1.96
South 851 9.2 0.90 0.68–1.20
Midwest 612 10.4 1.02 0.75–1.39
Socioeconomic status (in quartiles) < 0.001
Q1 1,557 15.5 1.00
Q2 1,550 11.1 0.72 0.57–0.90
Q3 1,502 11.1 0.72 0.57–0.89
Q4 1,405 5.5 0.36 0.27–0.48
Sufficiency of family income for expenses < 0.001
Always 2,037 4.0 1.00
Sometimes 1,520 8.1 2.04 1.49–2.79
Never 2,457 18.2 4.59 3.57–5.90
Health insurance coverage < 0.001
No 4,388 12.3 1.00
Yes 1,626 6.3 0.51 0.41–0.64
Physician explains about disease and treatment < 0.001
Always 4,960 9.3 1.00
Rarely/Never 1,054 16.9 1.81 1.49–2.21
No. of medical appointments in the last 12 months 0.019
0–1 1,384 8.4 1.00
2–3 1,992 10.8 1.29 1.00–1.66
4 or more 2,638 11.7 1.40 1.10–1.78
No. of medications used < 0.001
1 1,527 6.9 1.00
2–4 3,328 11.4 1.65 1.30–2.09
5 or more 1,159 13.7 1.98 1.50–2.61
a Unweighted by sample weight.
b Weighted by sample weight. 
c PR (95%CI): prevalence ratio (95% confidence interval), estimated by Poisson regression model with robust variance.
d Pearson’s chi-square test with Rao-Scott correction. 
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Table 4. Final results of the multivariate analysis of the characteristics associated with cost-related 
underuse of medications. Brazilian Longitudinal Study of Aging (ELSI-Brazil), 2015–2016. 
Variable Adjusted PRa 95%CI
Sex (ref: male)
Female 1.39 1.16–1.67b
Age (ref: 50–59 years)
60–79 0.75 0.63–0.89c
80 and over 0.43 0.28–0.67b




Sufficiency of monthly family income for expenses (ref: always)
Sometimes 1.74 1.28–2.35b
Never 2.94 2.29–3.79b
Health insurance coverage (ref: no)
Yes 0.79 0.63–0.98c
Frequency with which the physician explains about the disease and treatment (ref: frequently)
Rarely/Never 1.31 1.09–1.57c
Number of medications used (ref: 1)
2–4 1.39 1.11–1.74c
5 or more 1.53 1.16–2.02c
Self-rated health (ref: very good/good)
Fair 2.02 1.60–2.57b
Poor/Very poor 2.92 2.23–3.81b
Depression (ref: no)
Yes 1.69 1.41–2.02b
a Adjusted PR (95%CI): prevalence ratio estimated by Poisson regression model with robust variance, adjusted for 
all variables described in the table.
b p < 0.001
c p < 0.05
Table 3. Distribution of the variables of health needs according to cost-related underuse of medications. 







Self-rated health < 0.001
Very good/Good 2,299 4.3 1.00
Fair 2,905 11.9 2.75 2.16–3.53
Poor/Very poor 810 24.9 5.76 4.44–7.47
Hypertensiona
No 1,880 11.7 1.00
Yes 4,134 10.6 0.92 0.77–1.11 0.293
Diabetesa
No 4,718 10.5 1.00
Yes 1,296 11.1 1.05 0.86–1.30 0.623
Depressiona < 0.001
No 4,685 7.9 1.00
Yes 1,329 19.9 2.51 2.11–2.98
a Previous medical diagnosis 
b Unweighted.
c Weighted by sampling design .
d PR (95%CI): prevalence ratio (95% confidence interval), estimated by Poisson regression model with robust variance.
e Pearson’s chi-square test with Rao-Scott correction. 
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DISCUSSION
The main results of this analysis were: (1) approximately one in 10 study participants reported 
cost-related underuse of medications; (2) age, sex, and poor socioeconomic status (assessed 
by the score of household goods and perceived sufficiency of income) were important 
factors associated with underuse of medications; (3) the source of care (private health 
plan coverage), the quality of care (frequency with which the physician explains about the 
disease and treatment), and the number of medications used were also associated with the 
outcome; (4) persons with poorer self-rated health and with depression were more likely to 
have a cost-related underuse of medications. On the other hand, there were no associations 
between hypertension and diabetes and underuse of medications.
The frequency with which participants had a cost-related underuse of medications (10.6%) 
was similar to that observed among Canadian adults aged 18 years and over (9.9%)10 and 
higher than that observed in the United States, in the same age group (5.1%)7. In the age 
group of 60 years and over, the cost-related underuse of medications observed in this analysis 
(8.3%; data not shown) was higher in relation to European older adults (3.6%)6 but lower 
than that observed in the metropolitan area of Belo Horizonte, Brazil, (12.9%)13 and in the 
United States (20%)9. In addition to methodological issues related to how the outcome was 
defined, specificities of local policies for pharmaceutical care and coverage of the costs of 
medications may explain the above mentioned differences in prevalence.
Regarding predisposing factors, the prevalence of underuse of medications was higher 
among women and lower in  older ages, regardless of the enabling factors and factors of 
need. Women complain more intensely and frequently of health problems and use more 
medications than men, which result in higher costs with pharmacotherapy1,2. Higher 
spending with medications increases the financial pressure of women, who are more 
vulnerable than men in terms of income, socioeconomic status, and education level6,9. As for 
age, our results are in line with what has been reported in other populations4,8–10, showing 
that the cost-related underuse of medications decreases with age. With aging, health 
concern and vigilance increases, and non-adherence to treatment is perceived as harmful17.
The enabling variables are those that are more subject to modifications from public policies 
and the way health services are organized15. The financing of the costs with medications 
(partial or total subsidy to the prescribed medication, linked to specific care programs) can 
alleviate the financial pressures that hinder access18,19. The quality of the medical consultation 
(prescriptions that promote the rational use of medications, provision of explanations, and 
guidance to the patient), as well as pharmaceutical care services, can reduce the risks 
of non-adherence to the prescribed medication20. Income and socioeconomic status are 
the enabling factors most directly related to cost-related underuse, since they enable the 
individual to acquire medications. Our results are in line with other investigations that show 
consistent associations between higher income and lower underuse of medications4,7,8,10,13.
As with European older adults6, Brazilian older adults who perceive their family income as 
insufficient for expenses underuse more medications, regardless of other relevant factors 
including the score of household goods. Perceived sufficiency of household income for 
expenses is an important indicator of financial difficulties. Individuals with a similar income, 
but with a perception that their income is insufficient for expenses, usually react differently 
to the cost pressures involved in drug treatment, thus reducing the use in the face of a small 
increase in cost or adhering completely to the prescription, given the significant increase in 
the costs of medications2,11. Possibly other issues are considered in this process, such as the 
perception of the health risks involved or the value given to the medication in the treatment 
of the disease17. Our results support the hypothesis that expenses with medications can be 
disregarded when financial difficulties compel the individual to prioritize family expenses21.
Individuals covered by private health plan tend to present fewer financial barriers to the use 
of health services, as these barriers act by increasing social inequalities in access to these 
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services. This could explain the lower underuse of medications observed among participants 
with health plan coverage, which is consistent with results found in other countries4,7,8,10 
and in a Brazilian metropolitan region13.
The results regarding the greater underuse of medications among those with poorer 
socioeconomic status and those not covered by health plan reinforce the importance of 
governmental initiatives that seek to improve access to medications. The Brazilian Unified 
Health System (SUS) includes pharmaceutical care as a component of comprehensive health 
care, and the Brazilian Popular Pharmacy Program 22 is an important initiative to ensure this 
right to the citizen. This program can contribute with better adherence to pharmacological 
treatment among persons with lower socioeconomic level, especially those who live in 
places where public pharmaceutical care is not sufficiently organized. Recent studies have 
shown that, among Brazilians, a little more than a third of persons with hypertension and 
more than half of the persons with diabetes obtained at least one of the medications used 
to control their respective diseases in the Brazilian Popular Pharmacy Program 23, and 
approximately 72% of the medications used in the treatment of hypertension were obtained 
from the SUS and 16% was provided by this program  24. Our results showed no association 
of hypertension and diabetes with cost-related underuse of medications, in contrast to that 
observed for self-rated health and depression. This lack of association can be explained by 
the policies mentioned above.
As observed among Brazilian older adults (≥ 60 years)13 and among adults (≥ 18 years) from 
higher income countries8, our study identified a greater underuse of medications among 
those who did not feel well informed by the physician about their disease and treatment. 
Patients are more willing to overcome difficulties in acquiring medications when they are 
heard about their values and concerns (including financial ones) and when they have answers 
about the disease and its treatment5,8. The judgment of patients regarding accessibility 
to medication can vary and it may be difficult for the health professional to distinguish 
between inability to afford and unwillingness to purchase the medication needed for 
treatment10. Health professionals should be aware that the quality of information, including 
answering the patients’ questions, can increase adherence and, consequently, intensify the 
effectiveness of treatment. 
In our study, the number of medications used was associated with cost-related underuse. In 
addition to financial pressures, the amount of prescribed medications is considered as the 
main determinant of underuse, followed by individual characteristics (perceptions of the 
risks or benefits of the treatment) and the medication itself (possible side effect, complex 
administration)18,21. Health professionals can contribute minimizing underuse in these 
conditions when associating the quality of the prescription at an affordable cost. To this 
end, they can prescribe cheaper medications or increase the time needed for a prescription 
renewal, as well as give advice about the possibility of obtaining the medication in public 
pharmacies or in programs that provide subsidized medication.
Among the factors of need, poorer self-rated health and a previous medical diagnosis of 
depression were independently and positively associated with underuse of medications. 
The results related to self-rated health corroborate that observed in other populations7,8,10,13. 
Positive associations between cost-related underuse of medications and depression have 
been shown in another study8. In the United States, among those with chronic diseases, 
depression was associated with underuse of prescribed medications and those specific for 
the treatment of depression. Persons with depression may have impaired cognitive function 
and lower levels of energy and motivation, which may affect their willingness to spend on 
medications8. It is possible that the judgment of patients on the role of the medication in 
preventing the progression of the disease or the perception of a transitory nature of the 
depression may favor underuse among depressed individuals. Positive associations between 
poor health status and cost-related underuse of medication are worrying. Persons with 
poorer health conditions are at greater risk for the clinical consequences of non-adherence 
to the proposed therapeutic regimen10, as these consequences are minimized or ignored. 
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This study presents some limitations that hinder a more in-depth interpretation of its 
results. These limits refer to the impossibility of identifying the underused medication, 
which could indicate more clearly whether underuse is selective. Selectivity may reflect 
perceptions about the value of the proposed treatment and the importance of including 
the medication in the treatment. Aspects related to the provision and organization of 
health services, especially in relation to pharmaceutical care, can also contribute to this 
selectivity. On the other hand, the strength of the study arises from its comprehensiveness 
and the representativeness of the sample, which gives it originality. This is the first study 
to investigate cost-related underuse of medications which allows inference of its results to 
the Brazilian adult population aged 50 years and over.
In summary, our results point to the multidimensional and complex nature of the cost-related 
underuse of medications. Given the importance assumed by the medication in the treatment of 
different diseases, the costs they represent to patients, and the health risks of not adhering to 
the proposed pharmacotherapy, health professionals should strive to make treatment feasible. 
In this sense, the discussion with the patient about the disease and its treatment, the adequacy 
of the prescription to the patient’s ability to pay, and the provision of information that helps 
to overcome barriers to available medications should be offered. Regarding health planners, 
actions that enhance the universalization of pharmaceutical care, such as regular availability 
of medications in pharmacies of the SUS and the Brazilian Popular Pharmacy Program, can 
certainly contribute to reduce the underuse of medications and promote equality and equity 
in the access to them with positive impacts on the health of the population.
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